Nykode Therapeutics Management
Management criteria checks 1/4
Nykode Therapeutics' CEO is Michael Engsig, appointed in Sep 2019, has a tenure of 4.67 years. directly owns 0.005% of the company’s shares, worth NOK212.06K. The average tenure of the management team and the board of directors is 2.3 years and 2.5 years respectively.
Key information
Michael Engsig
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.7yrs |
| CEO ownership | 0.005% |
| Management average tenure | 2.3yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 02
Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)
Jan 22We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth
Aug 20Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business
Apr 06Could The Vaccibody AS (OB:VACC) Ownership Structure Tell Us Something Useful?
Jan 25
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$35m |
| Sep 30 2023 | n/a | n/a | -US$42m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$46m |
| Dec 31 2022 | n/a | n/a | -US$43m |
| Sep 30 2022 | n/a | n/a | -US$20m |
| Jun 30 2022 | n/a | n/a | -US$12m |
| Mar 31 2022 | n/a | n/a | -US$10m |
| Dec 31 2021 | US$567k | US$330k | -US$9m |
| Sep 30 2021 | n/a | n/a | US$147m |
| Jun 30 2021 | n/a | n/a | US$146m |
| Mar 31 2021 | n/a | n/a | US$146m |
| Dec 31 2020 | US$424k | US$280k | US$150m |
| Sep 30 2020 | n/a | n/a | -US$24m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | n/a | n/a | -US$15m |
| Dec 31 2019 | US$113k | US$106k | -US$14m |
Compensation vs Market: Insufficient data to establish whether Michael's total compensation is reasonable compared to companies of similar size in the Norwegian market.
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
CEO
Michael Engsig (51 yo)
4.7yrs
Tenure
US$567,000
Compensation
Mr. Michael Thyring Engsig is an Independent Director at FluoGuide A/S since March 21, 2023. He has been Chief Executive Officer of Nykode Therapeutics AS (formerly known as Vaccibody AS) since September 1...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 4.7yrs | US$567.00k | 0.0049% $ 212.1k | |
| Chief Scientific Officer & Co-founder | no data | no data | no data | |
| Chief Financial Officer | 3yrs | no data | 0.0092% $ 401.8k | |
| Chief Technology Officer | less than a year | no data | no data | |
| Chief Legal Officer | 2.3yrs | no data | no data | |
| Chief Research & Development Officer | 1.8yrs | no data | no data |
2.3yrs
Average Tenure
49.5yo
Average Age
Experienced Management: NYKD's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director | 10.3yrs | US$53.00k | 0.20% $ 8.7m | |
| Deputy Board Member | 2yrs | US$45.00k | 0.54% $ 23.8m | |
| Observer to the Board | no data | US$13.00k | no data | |
| Director | 4.3yrs | US$50.00k | 0.64% $ 28.2m | |
| Director | 2yrs | US$50.00k | no data | |
| Director | 3yrs | US$53.00k | 0.0062% $ 272.0k | |
| Director | 12.3yrs | US$60.00k | 0.10% $ 4.4m | |
| Chairman of the Board | no data | US$95.00k | 0.028% $ 1.2m | |
| Director | 2yrs | US$60.00k | no data | |
| Director | less than a year | US$50.00k | no data |
2.5yrs
Average Tenure
61yo
Average Age
Experienced Board: NYKD's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.